about
Retreatment with interferon plus ribavirin of chronic hepatitis C non-responders to interferon monotherapy: a meta-analysis of individual patient data.The association of IL28B genotype with the histological features of chronic hepatitis C is HCV genotype dependent.Multicentre randomised controlled trial of recombinant interferon alfa-2b in patients with acute non-A, non-B/type C hepatitis after transfusionLimited utility of ITPA deficiency to predict early anemia in HCV patients with advanced fibrosis receiving Telaprevir.Hepatitis C Virus Deletion Mutants Are Found in Individuals Chronically Infected with Genotype 1 Hepatitis C Virus in Association with Age, High Viral Load and Liver Inflammatory Activity.Serological Tests Do Not Predict Residual Fibrosis in Hepatitis C Cirrhotics with a Sustained Virological Response to Interferon.Pegylated IFN-alpha2a and ribavirin in the treatment of hepatitis C.Pegylated interferons alpha2a and alpha2b in the treatment of chronic hepatitis C.Antiviral therapy for HCV-associated cryoglobulinemic glomerulonephritis: case report and review of the literature.Inosine triphosphatase deficiency helps predict anaemia, anaemia management and response in chronic hepatitis C therapy.Ribavirin Impairs Salivary gland function During Combination Treatment With Pegylated Interferon Alfa-2a In HEpatitis C patients.HCV E1E2-MF59 vaccine in chronic hepatitis C patients treated with PEG-IFNα2a and Ribavirin: a randomized controlled trial.Ribavirin suppresses erythroid differentiation and proliferation in chronic hepatitis C patients.Interleukin 28B genotype and insulin resistance in chronic hepatitis C patients.Telaprevir in a patient with chronic hepatitis C and cryoglobulinemic glomerulonephritis.Sustained virological response prevents the development of insulin resistance in patients with chronic hepatitis C.Predictors of psychopathological outcome during peg-interferon and ribavirin therapy in patients with chronic HCV-correlated hepatitis.Randomized study of peginterferon-alpha2a plus ribavirin vs peginterferon-alpha2b plus ribavirin in chronic hepatitis C.Hepatitis C virus/human immunodeficiency virus coinfection in hemophiliacs: high rates of sustained virologic response to pegylated interferon and ribavirin therapy.Insulin resistance is associated with steatosis in nondiabetic patients with genotype 1 chronic hepatitis C.The clinical impact of a 24-week treatment course of peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia.Serum levels of hepatitis C virus RNA predict non-response to interferon therapy: comparison of two commercial assays.Twelve-week posttreatment follow-up predicts a sustained virological response to pegylated interferon and ribavirin therapy.Progressive hepatic fibrosis in healthy carriers of hepatitis C virus with a transaminase breakthrough.The course of esophageal varices in patients with hepatitis C cirrhosis responding to interferon/ribavirin therapy.Interleukin 28B polymorphism predicts pegylated interferon plus ribavirin treatment outcome in chronic hepatitis C genotype 4.Reduction in transmission of hepatitis C after the introduction of a heat-treatment step in the production of C1-inhibitor concentrate.Acute hepatitis B in children with papular acrodermatitis.Recovery after L-DOPA treatment in peginterferon and ribavirin induced parkinsonism.Persistence of "wild-type" and "e-minus" hepatitis B virus infection in chronic healthy HBsAg/anti-HBe positive carriers.Serum levels of hepatitis C virus core antigen as a marker of infection and response to therapy.Accelerated schedule of hepatitis B vaccination in patients with hemophilia.Specificity of hepatitis C antibody ELISA in patients with haemophilia.A 28-year study of the course of hepatitis Delta infection: a risk factor for cirrhosis and hepatocellular carcinoma.The diagnostic accuracy of Fibroscan for cirrhosis is influenced by liver morphometry in HCV patients with a sustained virological response.HCV-RNA kinetics on-treatment do not predict sustained virologic response in HCV genotype 3 patients receiving sofosbuvir and ribavirin.Implications of PNPLA3 polymorphism in chronic hepatitis C patients receiving peginterferon plus ribavirin.Onset of inflammatory bowel diseases during combined alpha-interferon and ribavirin therapy for chronic hepatitis C: report of two cases.Treatment of chronic hepatitis C in Europe.Natural history and clinical impact of cryoglobulins in chronic hepatitis C: 10-year prospective study of 343 patients.
P50
Q30746310-5BF33F7B-FC60-48FC-B60B-763794DB828CQ33755525-B867AF2B-1BCC-44FD-AF69-B93B40CA9CCFQ34375921-285162BA-0BBF-4C14-8F5D-9E115D682701Q35156156-DEF5C0A4-1DE3-408A-B44B-C640FBF0B33BQ35787526-A777AE4B-4F55-427C-B928-85FA153D1F8BQ36052963-BDEAED9D-B065-4DEB-A159-9415890A3A1EQ37608271-BD8518BE-8075-4028-832A-4BF83DFD3DF1Q37774238-FD258E3E-6CE6-4CD4-B747-0AD34C155D09Q38073147-8618675D-9D63-4D0F-BBAB-19A628FA6715Q40155391-97432A95-A9AA-4725-80D6-E4DBBBDF401EQ40753034-177D0252-F654-4937-849A-C6B579D02CD8Q42223373-F88A08F8-655C-41B9-A676-707B454AA54DQ42223386-35EBA5D6-C49F-47F3-9F37-61FB52D40E65Q42237363-FF1B3F3C-2923-4ECD-8039-B994D75EBC02Q42271855-561F6487-A3CF-48C8-9A1A-FD732233D359Q42980606-DBF1CF34-4204-4A68-96AF-2D191BEE5D0EQ42987674-E88E04F2-FA67-4E0E-B5DD-B04E9736B9EFQ42991111-133167D0-B9F6-4AEA-B4C5-B3918E1855EAQ42991475-E0E23AFA-CC67-41F7-970D-52E2749795CFQ42997332-19117ABC-A1AB-4F8E-8256-38AFCBE2FD5FQ42998773-71B55830-42DC-4789-9F52-0996E4F351ADQ42998924-429B2611-4FD8-4406-93F5-DB9A1089CE46Q42999597-5FE0DF74-D1EF-4672-A0FE-74E7B3A9C62DQ43036622-9BD44557-A544-4A58-9679-027E903F9193Q43039467-E7A3A6E1-E3A4-472E-B0F6-3D1F4A6053A6Q43040683-919322E6-5EED-41EE-B29F-C1DF36427DC0Q43040906-56CBC416-18D7-4A28-B7AE-129EBDB3B64AQ43510018-344ECBFE-74AB-4BE7-B6C0-7ED806E44901Q44108143-A9B25D77-1DD3-41B2-AB96-42567B2944B0Q44599784-7E57EA11-4B88-4A41-B30F-B8033800B61CQ45596801-76CABEC3-772E-4D81-86C6-2E3E7F0E3311Q45873708-91B804EC-062E-4BFC-94FE-6703C9124059Q45881795-9E880AB2-1A39-444A-BE81-DC78EEB132AEQ46126089-C47C2B5E-F747-4B09-91E8-2F631F7E3BC1Q46713524-4770ADFC-1618-47A0-B074-8171A9D07E1DQ50269027-9FF58BAA-0542-4A37-8E2E-CE8003759F3FQ50552325-95162680-A977-426E-883F-54145042E93AQ50577813-DF7A8980-ECD7-4714-B4B3-AC8E769A1CF2Q50582432-AA100190-DBAB-42C6-A462-7F219F4642AAQ51743328-7281C151-08D6-43EC-A073-4DA000C562AE
P50
description
Forscher
@de
chercheur
@fr
investigador
@es
researcher
@en
հետազոտող
@hy
研究者
@zh
name
Mariagrazia Rumi
@ast
Mariagrazia Rumi
@en
Mariagrazia Rumi
@es
Mariagrazia Rumi
@nl
type
label
Mariagrazia Rumi
@ast
Mariagrazia Rumi
@en
Mariagrazia Rumi
@es
Mariagrazia Rumi
@nl
altLabel
Rumi MG
@en
prefLabel
Mariagrazia Rumi
@ast
Mariagrazia Rumi
@en
Mariagrazia Rumi
@es
Mariagrazia Rumi
@nl
P106
P1153
7005192361
P31
P4012
P496
0000-0002-5876-8528